Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy.
about
Emerging concepts for PI3K/mTOR inhibition as a potential treatment for osteosarcomaEverolimus in the management of metastatic renal cell carcinoma: an evidence-based review of its place in therapyAddition of Everolimus Post VEGFR Inhibition Treatment Failure in Advanced Sarcoma Patients Who Previously Benefited from VEGFR Inhibition: A Case SeriesColon Cancer Tumorigenesis Initiated by the H1047R Mutant PI3K.Pazolimus: pazopanib plus sirolimus following progression on pazopanib, a retrospective case series analysis.Prospective phase II trial of everolimus in PIK3CA amplification/mutation and/or PTEN loss patients with advanced solid tumors refractory to standard therapy.Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors.Efficient Promotion of Autophagy and Angiogenesis Using Mesenchymal Stem Cell Therapy Enhanced by the Low-Energy Shock Waves in the Treatment of Erectile Dysfunction
P2860
Q26738598-39CA5815-1906-4CA5-8690-4A97FF23978AQ28079861-E2A534A6-3CE0-4E4F-B45C-E0BACE085426Q28550228-56A61961-0371-4051-8F95-2222B107FFCDQ35919716-2723C6D4-FCAD-48B1-98FE-869F1AFF0A0DQ36097737-F2C08B38-C304-46A4-84E8-F92D02642E3AQ36318871-540B6660-07A4-468C-8004-D4BF160722B4Q44727423-7B0D6701-BFCE-4735-AED0-8B9A90D9E77CQ57167048-F4583BA7-C971-4BB2-B2DE-284F870920E4
P2860
Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy.
description
2015 nî lūn-bûn
@nan
2015 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Phase I combination of pazopan ...... efractory to standard therapy.
@ast
Phase I combination of pazopan ...... efractory to standard therapy.
@en
type
label
Phase I combination of pazopan ...... efractory to standard therapy.
@ast
Phase I combination of pazopan ...... efractory to standard therapy.
@en
prefLabel
Phase I combination of pazopan ...... efractory to standard therapy.
@ast
Phase I combination of pazopan ...... efractory to standard therapy.
@en
P2093
P2860
P50
P1476
Phase I combination of pazopan ...... efractory to standard therapy.
@en
P2093
Bettzy Stephen
Daniel Karp
David Hong
Gerald Falchook
Heloisa Veasey Rodrigues
Jennifer Wheler
Jorge Bellido
Ralph Zinner
P2860
P2888
P304
P356
10.1007/S10637-015-0238-2
P577
2015-04-24T00:00:00Z
P6179
1009599371